JPS56108712A - Lecithin cholesterol acyl transferase activator - Google Patents
Lecithin cholesterol acyl transferase activatorInfo
- Publication number
- JPS56108712A JPS56108712A JP1073780A JP1073780A JPS56108712A JP S56108712 A JPS56108712 A JP S56108712A JP 1073780 A JP1073780 A JP 1073780A JP 1073780 A JP1073780 A JP 1073780A JP S56108712 A JPS56108712 A JP S56108712A
- Authority
- JP
- Japan
- Prior art keywords
- lecithin
- pantethine
- activator
- lcat
- acyl transferase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
PURPOSE:The titled activator that uses pantethine and lecithin as effective components, thus being effective on coronary arteriosclerosis. CONSTITUTION:Pantethine and lecithine are used as effective components to produce a lecithin chloesterol acyl transferase activator (abbreviated to LCAT). Patients with coronary arterioscelerosis, renal diseases or diabetes are observed to have activity-lowered LCAT in blood and the combined administration of pantethine together with lecithin has been found to increase the LCAT activity remarkably. Therefore, the combination is expected to be effective on these diseases. Usually, 1,000-2,000mg of pantethine and 5-7g of lecithin are orally administered a day.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1073780A JPS56108712A (en) | 1980-01-31 | 1980-01-31 | Lecithin cholesterol acyl transferase activator |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1073780A JPS56108712A (en) | 1980-01-31 | 1980-01-31 | Lecithin cholesterol acyl transferase activator |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS56108712A true JPS56108712A (en) | 1981-08-28 |
JPS6345371B2 JPS6345371B2 (en) | 1988-09-09 |
Family
ID=11758600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1073780A Granted JPS56108712A (en) | 1980-01-31 | 1980-01-31 | Lecithin cholesterol acyl transferase activator |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS56108712A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995034811A1 (en) * | 1993-06-11 | 1995-12-21 | Oculon Corporation | Protein condensation inhibitors and methods related thereto |
WO2015050148A1 (en) * | 2013-10-04 | 2015-04-09 | 第一三共株式会社 | 3-arylpyrazolopyridine derivative |
WO2015076353A1 (en) * | 2013-11-25 | 2015-05-28 | 第一三共株式会社 | 3-alkylpyrazolopyridine derivative |
-
1980
- 1980-01-31 JP JP1073780A patent/JPS56108712A/en active Granted
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995034811A1 (en) * | 1993-06-11 | 1995-12-21 | Oculon Corporation | Protein condensation inhibitors and methods related thereto |
WO2015050148A1 (en) * | 2013-10-04 | 2015-04-09 | 第一三共株式会社 | 3-arylpyrazolopyridine derivative |
WO2015076353A1 (en) * | 2013-11-25 | 2015-05-28 | 第一三共株式会社 | 3-alkylpyrazolopyridine derivative |
Also Published As
Publication number | Publication date |
---|---|
JPS6345371B2 (en) | 1988-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2047686A1 (en) | Dietary supplement for insulin-resistant diabetics | |
EP0151989A3 (en) | Means for the treatment of cardiac diseases | |
ATE204178T1 (en) | METHOD FOR TREATING AND PREVENTING TYPE 1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN | |
NO951592L (en) | Process for the preparation of a transdermal therapeutic system | |
ATE66614T1 (en) | INSULIN PREPARATION FOR NON-PARENTERAL ADMINISTRATION. | |
AU2506388A (en) | Azelastine-containing medicaments for application in the nose and/or at the eye | |
ES8201596A1 (en) | their preparation and use as medicines. | |
PL287844A1 (en) | Method of obtaining an oraly administered composite medicine for treating interstinal inflamatory diseases | |
DE3575076D1 (en) | CATHETER FOR BACK INFUSION OF PHARMACEUTICAL AGENTS. | |
ATE65696T1 (en) | USE OF DEFIBROTID IN THE TREATMENT OF ACUTE KIDNEY FAILURE CONDITIONS. | |
ATE65912T1 (en) | MEDICINAL COMPOSITIONS OF REDUCED TOXICITY. | |
EP0302714A3 (en) | Pharmaceutical composition for treatment of bone-wasting diseases | |
JPS56108712A (en) | Lecithin cholesterol acyl transferase activator | |
FR2362849A1 (en) | NEW HETEROCYCLO-OMEGA-PENTANORPROSTAGLANDINS ARYLIC SUBSTITUTES IN POSITION 2 AND MEDICINAL PRODUCTS CONTAINING THEM | |
FR2428649A1 (en) | DIESTERS IN 17,21 OF HYDROCORTISONE AND MEDICINAL PRODUCTS CONTAINING SAME | |
EG17992A (en) | Preparation of a medicament for arthritis and theumatism | |
NO862321D0 (en) | PHYSIOLOGICAL AGENT FOR INCREASING TRANSDERMAL DELIVERY OF MEDICINAL PRODUCTS. | |
MY114218A (en) | The use of bambuterol or a pharmaceutically acceptable salt thereof, to make lipid lowering pharmaceutical preparations. | |
KR880010762A (en) | Composition and Method for Treatment of peptic Ulcers | |
ATE55254T1 (en) | REDUCING THE TOXIC EFFECTS OF ANTHRACHINONE MEDICATIONS. | |
SU637117A1 (en) | Method of tuberculosis diagnosis | |
Rich et al. | Agranulocytosis resulting from methimazole (tapazole): report of three cases | |
熊宁宁 et al. | EFFECTS OF TCM THERAPY ON THE PROGRESSION OF CHRONIC RENAL FAILURE CAUSED BY PRIMARY GLOMERULONEPHRITIS | |
Cidad | Metabolic effects of beta-blocking drugs. Their association with diuretics in the treatment of arterial hypertension. | |
UA15281A (en) | Method for treatment of chronic coronary heart disease |